Although, as far as we know, synergistic combinations targeting these pathways have been previously studied for pancreatic cancer, especially in the context of KRAS mutants (>90% of pancreatic cancer patients are KRAS mutants)35, this is the first evidence of potential synergistic effect between PHT-427 and AZD6244. The gene discussed is KRAS; the disease is familial pancreatic carcinoma.